Focuses on developing immuno-oncology therapies targeting the tumor microenvironment to enhance antitumor immune responses.
Estrella Immunopharma, Inc. is an emerging biopharmaceutical company in the preclinical stage, dedicated to advancing innovative T-cell therapies designed for treating both blood cancers and solid tumors across the United States.
At the forefront of Estrella Immunopharma's pipeline are its lead product candidates. EB103 is currently under preclinical evaluation for the treatment of diffuse large B-cell lymphoma, while EB104 aims to target both diffuse large B-cell lymphoma and acute lymphocytic leukemia.
In pursuit of groundbreaking therapies, Estrella Immunopharma has forged a strategic partnership with Imugene Limited. This collaboration focuses on combining Imugene's product candidate CF33-CD19t with Estrella's EB103, aiming to develop effective treatments for solid tumors.
Headquartered in Emeryville, California, Estrella Immunopharma is strategically situated within the biotechnology landscape, poised to leverage its research and partnerships to bring promising T-cell therapies to patients in need of novel treatment options for challenging cancers.